Really proud to share the part of my postdoctoral work from @kaelin_lab that came out in @CD_AACR online first. See below for the key findings of our study.

Fastest ODI hundreds for India (Men’s or Women’s) 🇮🇳🏏

"Making sense of low-complexity domains: The 2025 Lasker Basic Science Award" #LaskerAward #Lasker2025 #phaseseparation #structuralbiology https://t.co/v5EWYiNBTW

What a terrific recognition of our research field! Dirk Görlich (Max Planck Institute Göttingen) & Steven McKnight (UT Southwestern) received the Lasker Award for their work on low-complexity domains & their phase separation. Read the perspective in PNAS: https://t.co/mTYWZf1lGv

Thrilled to share our work to find natural products that inhibit β-catenin! This is the result of an amazing collaboration with @theNCI Natural Products Branch and shows the power of 'up' assays to find new and interesting molecules!

Join us for The Science of Childhood Cancer lecture series hosted by @StJudeResearch this Thursday, August 14 at 12 CT/1pm ET where Bill will be presenting The Von Hippel-Lindau tumor suppressor: insights into oxygen sensing, tumor immunity, and drugging the undruggable.

From the July issue: Requirement for Cyclin D1 Underlies Cell Autonomous HIF2-Dependence in Kidney Cancer https://t.co/ON6ZpUYjAr By @nitin_shirole89, @kaelin_lab, and colleagues at @DanaFarber

Through tirelessly efforts, our graduate student @cheni_hsu published a manuscript in @STARProtocols to reconstitute enzymatic activities for ultra-large (>300kDa) histone methyltransferases NSD1 and SETD2. To our best knowledge, this is the first time their full-length forms

Thank you boys for your support , good luck at @HomeOfCricket

@TumorBoardTues @brian_rini @IntegrityCE @DrRanaMcKay @montypal @katy_beckermann @JVentoMD @mzugman @DrChoueiri @tompowles1 @TiansterZhang @kidneycan @CParkMD @JadChahoud @alantanmd @Uromigos @AlbigesL @SoaresAndrey @dsahil320 @chefaleixomd @JBrugarolas @YuWeiChenMD @HHammersMD 5/17 #TumorBoardTuesday 👨🏽‍🏫Mini Tweetorial 2👨🏽‍🏫 Summary 🗓️ m60mo FU, n = 61, 97% prior 🔪 🩻 OR 70% RCC, 50% 🧠, 90% pNET, 100% 👁️, mTTR 8.5 mo ⬇️ 75% no. 🔪 and 44% ⬇️ in pts requiring 🔪

Thank you Temba and the rest!

In 2023, the @FDA approved belzutifan for certain kidney cancers –– thanks to years of work led by Nobel Prize recipient William G. Kaelin Jr., MD, @kaelin_lab. Now, @DrChoueiri, director of @DanaFarber_GU, and team are working to expand its clinical use. https://t.co/WRNZ0ByKgb

#ASCO25 Excellent summary slide of trials of HIF-2α inhibitor therapy in refractory RCC 📷@TiansterZhang @urotoday

I have a baby lab! We have some exciting questions on developmental neuroscience. Please apply if interested in joining me

🌟Insightful, data-rich, and clinically grounded presentation by @crisuarez08 at #IKCSEU25 @KidneyCancer @OncoAlert 🟠 Belzutifan shows 49% ORR and 98% clinical benefit in VHL-associated RCC 🟠 Strong responses also seen in pancreatic (77%) and neuroendocrine tumors (94%) 🟠

We had a great time celebrating the group's many accomplishments!

We report that Cyclin D1 is an important direct target of HIF2 that drives the proliferation of ccRCC. Our findings further support the notion of combining HIF2 and CDK4/6 inhibitors to enhance antitumor activities. Congrats to @nitin_shirole89 and the team!

New study just out from @kaelin_lab in @CD_AACR elucidating more about the dependence of #kidneycancer tumor cells on HIF2, implicating Cyclin D1 activity in resistance mechanisms to HIF2-targeted therapy

Importantly, I am very grateful for the support of @HopeFunds1 and @df_hcc Kidney Cancer SPORE to provide critical funding for my research.

6) Our findings further support the notion of combining HIF2 and CDK4/6 inhibitors to attain deeper and more frequent tumor regressions in kidney cancer.

5) The antitumor effects of HIF2 inhibitors appears to involve both cell-intrinsic effects through Cyclin D1 and cell-extrinsic effects through VEGF.